Vancouver, British Columbia–(Newsfile Corp. – September 1, 2020) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf“, “OILS“, or the “Company“), is pleased to provide an innovation update on its patent pending Rapid Emulsion Technology by OILS^™ developed for cannabinoid infused products.

[youtube https://www.youtube.com/watch?v=2jgo56W7wvU]

Cannot view this video? Visit:
https://www.youtube.com/watch?v=2jgo56W7wvU

Nextleaf has completed successful scale trials for a variety of market-validated product formats manufactured with the Company’s patent pending technology.

Ten years of collective R&D has resulted in a proprietary delivery system that has been adapted to cannabis, increasing bioavailability through micro and nano emulsification to deliver rapid onset of THC, CBD, and other cannabinoids. OILS currently has a pending to issued patent allowance success rate of 100%, with over 40 issued patents globally.

The commercial launch of this innovative technology comes within a year of the legalization of cannabis 2.0 products across Canada. Rapid Emulsion Technology by OILS^™ can be used in a variety of infused product formulations including ready-to-drink beverages and ingestible concentrates.

Nextleaf has commenced further innovation and development of a powdered cannabinoids product based on the core Rapid Emulsion Technology by OILS^™. Using Nextleaf’s high purity distillate, alongside microscopic amounts of natural carrier oils and food-grade emulsifiers, the unique droplet structure allows the final ingredient to be virtually tasteless, odorless, and achieve optical transparency through uniform and complete dispersion of the particle into water.

“Our patent pending technology provides exceptional stability when developing a wide range of infused products such as edibles and beverages. Being able to accommodate different flavors, potency, and pH values – with ease – provides greater flexibility and speed-to-market advantages during product development,” said Emma Andrews, Director of Marketing at Nextleaf.

Rapid Emulsion Technology by OILS^™ delivers on an existing consumer need for value-added products beyond combustible cannabis that are portable and offer discreet methods of consumption with reliable and predictable onset. This technology extends OILS’ range of services and depth of expertise along the value-added product spectrum. Complimenting Nextleaf’s demonstrated excellence in efficiently processing high purity distillate, Rapid Emulsion Technology by OILS^™ will be available to B2B partners as an additional service alongside toll processing, bulk ingredient sales, IP licensing, and R&D.

About Nextleaf®

OILS is Canada’s most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. OILS provides extraction services and wholesale of THC and CBD oils through its wholly owned subsidiary Nextleaf Labs Ltd., a Health Canada licensed standard processor. The Company’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils. OILS is the first public company to be issued U.S. patents for industrial-scale extraction and distillation of cannabinoids. The Company owns a portfolio of over 40 issued patents and over 60 pending patents for the extraction, purification, and delivery of cannabinoids.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

www.nextleafsolutions.com

For more information, please contact:

Jason McBride
604-283-2301 (ext. 219)
[email protected]

On behalf of the Board of Directors of OILS,
Paul Pedersen, CEO

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed, approved or disapproved the contents of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62974